Short Interest in InflaRx (NASDAQ:IFRX) Declines By 13.7%

InflaRx (NASDAQ:IFRX) saw a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 415,200 shares, a drop of 13.7% from the January 15th total of 481,300 shares. Based on an average trading volume of 305,500 shares, the short-interest ratio is currently 1.4 days.

InflaRx Price Performance

Shares of IFRX opened at $2.00 on Tuesday. InflaRx has a 1 year low of $1.16 and a 1 year high of $2.82. The company’s 50 day simple moving average is $2.41 and its 200 day simple moving average is $1.92.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of InflaRx in a report on Thursday, January 16th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Two Sigma Securities LLC acquired a new stake in InflaRx in the fourth quarter valued at approximately $28,000. Walleye Capital LLC purchased a new position in InflaRx in the 4th quarter valued at about $51,000. Cubist Systematic Strategies LLC purchased a new position in InflaRx in the 4th quarter valued at about $55,000. Geode Capital Management LLC grew its stake in shares of InflaRx by 32.8% during the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock valued at $119,000 after acquiring an additional 11,900 shares in the last quarter. Finally, Commonwealth Equity Services LLC lifted its stake in shares of InflaRx by 20.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock worth $275,000 after acquiring an additional 19,000 shares in the last quarter. 42.39% of the stock is owned by institutional investors and hedge funds.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.